Q32 Bio Inc. announced the appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer on September 14, 2026. Dr. Trevejo joins from Enveda Therapeutics, where he served as CMO and Head of Clinical Pipeline Strategy, having previously held leadership roles at Tarsus Pharmaceuticals and Rocket Pharmaceuticals. Dr. Hershberger comes from EMH Consulting LLC after serving as Chief Development Officer at Adagio Therapeutics (now Invivyd). These hires support the company's transition to late-stage clinical development for its lead candidate, bempikibart, a fully human anti-IL-7Rα antibody being evaluated for alopecia areata and other autoimmune diseases. Q32 Bio is a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases.